BRCA1 and prostate carcinoma: Dose response curves were performed with carboplatin (Fig. 5h) and the PARPi olaparib (Fig. 5i) using various prostate cancer lines, plus BRCA1-deficient UWB1.289 ovarian cancer cells as a bona fide HRd control (56).